31501-48-1

Usage

Uses

Used in Pharmaceutical Industry:
Arenaemycin E is used as an antibiotic for treating various bacterial infections. Its antibiotic activity is attributed to its ability to inhibit bacterial cell wall synthesis, leading to cell lysis and death. This makes it a crucial component in the development of new antibiotics to combat drug-resistant bacteria.
Used in Research and Development:
Arenaemycin E is also used as a research tool in the study of bacterial resistance mechanisms and the development of novel antimicrobial agents. Its unique structure and mode of action provide valuable insights into the design of new drugs to overcome the challenges posed by antibiotic resistance.
Used in Agricultural Industry:
In addition to its medical applications, arenaemycin E can be used as a biopesticide in the agricultural industry. Its antimicrobial properties can help control bacterial infections in crops, reducing the need for chemical pesticides and promoting sustainable farming practices.

Upstream product

• 85416-36-0 pentalenolactone F 

Relevant academic research and scientific papers

Genome mining in Streptomyces. Discovery of an unprecedented P450-catalyzed oxidative rearrangement that is the final step in the biosynthesis of pentalenolactone

The penM and pntM genes from the pentalenolactone biosynthetic gene clusters of Streptomyces exfoliatus UC5319 and Streptomyces arenae TUe469 were predicted to encode orthologous cytochrome P450s, CYP161C3 and CYP161C2, responsible for the final step in the biosynthesis of the sesquiterpenoid antibiotic pentalenolactone (1). Synthetic genes optimized for expression in Escherichia coli were used to obtain recombinant PenM and PntM, each carrying an N-terminal His6-tag. Both proteins showed typical reduced-CO UV maxima at 450 nm, and each bound the predicted substrate, pentalenolactone F (4), with KD values of 153 ± 14 and 126 ± 11 μM for PenM and PntM, respectively, as determined by UV shift titrations. PenM and PntM both catalyzed the oxidative rearrangement of 4 to 1 when incubated in the presence of NADPH, spinach ferredoxin, ferredoxin reductase, and O2. The steady-state kinetic parameters were kcat = 10.5 ± 1.7 min-1 and Km = 340 ± 100 μM 4 for PenM and kcat = 8.8 ± 0.9 min-1 and Km = 430 ± 100 μM 4 for PntM. The in vivo function of both gene products was confirmed by the finding that the corresponding deletion mutants S. exfoliatus/ΔpenM ZD22 and S. arenae/ΔpntM ZD23 no longer produced pentalenolactone but accumulated the precursor pentalenolactone F. Complementation of each deletion mutant with either penM or pntM restored production of antibiotic 1. Pentalenolactone was also produced by an engineered strain of Streptomyces avermitilis that had been complemented with pntE, pntD, and either pntM or penM, as well as the S. avermitilis electron-transport genes for ferredoxin and ferrodoxin reductase, fdxD and fprD.